BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 32165065)

  • 1. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
    Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
    Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study
    Bandini M; Gibb EA; Gallina A; Raggi D; Marandino L; Bianchi M; Ross JS; Colecchia M; Gandaglia G; Fossati N; Pederzoli F; Lucianò R; Colombo R; Salonia A; Briganti A; Montorsi F; Necchi A
    Ann Oncol; 2020 Dec; 31(12):1755-1763. PubMed ID: 32979511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Necchi A; Bandini M; Calareso G; Raggi D; Pederzoli F; Farè E; Colecchia M; Marandino L; Bianchi M; Gallina A; Colombo R; Fossati N; Gandaglia G; Capitanio U; Dehò F; Giannatempo P; Lucianò R; Salonia A; Madison R; Ali SM; Chung JH; Ross JS; Briganti A; Montorsi F; De Cobelli F; Messina A
    Eur Urol; 2020 May; 77(5):636-643. PubMed ID: 31882281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    Briganti A; Gandaglia G; Scuderi S; Gallina A; Colombo R; Fossati N; Barletta F; Pellegrino A; Nocera L; Montorsi F; Necchi A
    Eur Urol; 2020 May; 77(5):576-580. PubMed ID: 31911010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Urol Oncol; 2021 Apr; 39(4):235.e15-235.e21. PubMed ID: 33071107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
    Necchi A; Raggi D; Giannatempo P; Marandino L; Farè E; Gallina A; Colecchia M; Lucianò R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Dittamore R; Liu Y; Davicioni E; Ross JS; de Jong JJ; Briganti A; Montorsi F; Gibb EA
    Eur Urol Oncol; 2021 Dec; 4(6):1001-1005. PubMed ID: 32417369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    Necchi A; Basile G; Gibb EA; Raggi D; Calareso G; de Padua TC; Patanè D; Crupi E; Mercinelli C; Cigliola A; Tateo V; Giannatempo P; Moschini M; Briganti A; Montorsi F; Messina A; Ross JS; Pavlick D; De Cobelli F; Brembilla G
    BJU Int; 2024 Feb; 133(2):214-222. PubMed ID: 37803523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition.
    Necchi A; Raggi D; Gallina A; Bandini M; de Jong JJ; Marandino L; Briganti A; Montorsi F; Davicioni E; Lotan Y; Gibb EA
    Urol Oncol; 2021 Oct; 39(10):734.e11-734.e17. PubMed ID: 34301456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.